Abstract
Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1146-1153 |
| Number of pages | 8 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 17 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2011 |
Fingerprint
Keywords
- Autologous peripheral blood stem cell transplantation
- Cell dose
- Platelet recovery
- Plerixafor
ASJC Scopus subject areas
- Transplantation
- Hematology
Cite this
Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma. / Stiff, Patrick J.; Micallef, Ivana; Nademanee, Auayporn P.; Stadtmauer, Edward A.; Maziarz, Richard; Bolwell, Brian J.; Bridger, Gary; Marulkar, Sachin; Hsu, Frank J.; DiPersio, John F.
In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 8, 08.2011, p. 1146-1153.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma
AU - Stiff, Patrick J.
AU - Micallef, Ivana
AU - Nademanee, Auayporn P.
AU - Stadtmauer, Edward A.
AU - Maziarz, Richard
AU - Bolwell, Brian J.
AU - Bridger, Gary
AU - Marulkar, Sachin
AU - Hsu, Frank J.
AU - DiPersio, John F.
PY - 2011/8
Y1 - 2011/8
N2 - Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.
AB - Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34 + cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34 + cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34 + cell dose levels: 2-4 × 10 6 cells/kg, 4-6 × 10 6 cells/kg, and >6 × 10 6 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34 + cell dose and the proportion of patients with platelet count >150 × 10 9/L at 100 days (P <.001), 6 months (P = 026), and 12 months (P = 020) in patients with NHL, and at 100 days in patients with MM (P = 004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 10 9/L at 100 days (P <.001) and 6 months (P = 023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = 006). Our analyses confirm previous findings that transplanted CD34 + cell dose may be associated with better long-term platelet recovery after ASCT.
KW - Autologous peripheral blood stem cell transplantation
KW - Cell dose
KW - Platelet recovery
KW - Plerixafor
UR - http://www.scopus.com/inward/record.url?scp=79960216473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960216473&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2010.11.021
DO - 10.1016/j.bbmt.2010.11.021
M3 - Article
VL - 17
SP - 1146
EP - 1153
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 8
ER -